Untangling Genetic Risk for Alzheimer's Disease

Biological Psychiatry

Volumn 83, Issue 4, 2018, Pages 300-310

  Pimenova, Anna A ^a   Raj, Towfique ^a   Goate, Alison M ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Endolysosomal pathway; Functional genomics; Genome wide association studies; Immune response; Lipid metabolism

Indexed keywords

APOLIPOPROTEIN E; CD2 ASSOCIATED PROTEIN; PHOSPHATIDYLINOSITOL BINDING CLATHRIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ENDOCYTOSIS; ENDOPHENOTYPE; EPIGENETICS; FUNCTIONAL GENOMICS; GENE MUTATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOME-WIDE ASSOCIATION STUDY; HUMAN; IMMUNE RESPONSE; LIPID METABOLISM; NEUROPATHOLOGY; NONHUMAN; ONSET AGE; PRIORITY JOURNAL; REVIEW; TRANSCRIPTOMICS; ANIMAL; GENETICS; IMMUNOLOGY; METABOLISM; PATHOPHYSIOLOGY;

ALZHEIMER DISEASE; ANIMALS; GENOME-WIDE ASSOCIATION STUDY; HUMANS;

EID: 85021274252     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2017.05.014     Document Type: Review

References (144)

1. Holtzman, D.M., Morris, J.C., Goate, A.M., Alzheimer's disease: The challenge of the second century. Sci Transl Med, 3, 2011, 77sr1.
2. Gómez-Isla, T., Price, J.L., McKeel, D.W., Morris, J.C., Growdon, J.H., Hyman, B.T., Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci 16 (1996), 4491–4500.
3. Murray, C., Viehman, A., Lippa, C.F., The corpus callosum in Pick's disease, Alzheimer's disease, and amyotrophic lateral sclerosis: Gliosis implies possible clinical consequence. Am J Alzheimers Dis Other Demen 21 (2006), 37–43.
4. Qiu, C., Kivipelto, M., Von Strauss, E., Epidemiology of Alzheimer's disease: Occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci 11 (2009), 111–128.
5. Goate, A., Chartier-Harlin, M.C., Mullan, M., Brown, J., Crawford, F., Fidani, L., et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349 (1991), 704–706.
6. Sherrington, R., Rogaev, E.I., Liang, Y., Rogaeva, E.A., Levesque, G., Ikeda, M., et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375 (1995), 754–760.
7. Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D.M., Pettingell, W.H., Yu, C., et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 269 (1995), 973–977.
8. Rogaev, E.I., Sherrington, R., Rogaeva, E.A., Levesque, G., Ikeda, M., Liang, Y., et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 376 (1995), 775–778.
9. Guerreiro, R.J., Gustafson, D.R., Hardy, J., The genetic architecture of Alzheimer's disease: Beyond APP, PSENS and APOE. Neurobiol Aging 33 (2012), 437–456.
10. Selkoe, D.J., Hardy, J., The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med 8 (2016), 595–608.
11. Gatz, M., Reynolds, C.A., Fratiglioni, L., Johansson, B., Mortimer, J.A., Berg, S., et al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry 63 (2006), 168–174.
12. Mastroeni, D., McKee, A., Grover, A., Rogers, J., Coleman, P.D., Epigenetic differences in cortical neurons from a pair of monozygotic twins discordant for Alzheimer's disease. PLoS One, 4, 2009, e6617.
13. Sleegers, K., Brouwers, N., Gijselinck, I., Theuns, J., Goossens, D., Wauters, J., et al. APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy. Brain 129 (2006), 2977–2983.
14. Rovelet-Lecrux, A., Hannequin, D., Raux, G., Le Meur, N., Laquerrière, A., Vital, A., et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 38 (2006), 24–26.
15. Mullan, M., Crawford, F., Axelman, K., Houlden, H., Lilius, L., Winblad, B., Lannfelt, L., A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet 1 (1992), 345–347.
16. Zhou, L., Brouwers, N., Benilova, I., Vandersteen, A., Mercken, M., Van Laere, K., et al. Amyloid precursor protein mutation E682K at the alternative beta-secretase cleavage beta’-site increases Abeta generation. EMBO Mol Med 3 (2011), 291–302.
17. Benilova, I., Karran, E., De Strooper, B., The toxic Aβ oligomer and Alzheimer's disease: An emperor in need of clothes. Nat Neurosci 15 (2012), 349–357.
18. Saito, T., Suemoto, T., Brouwers, N., Sleegers, K., Funamoto, S., Mihira, N., et al. Potent amyloidogenicity and pathogenicity of Aβ43. Nat Neurosci 14 (2011), 1023–1032.
19. Chávez-Gutiérrez, L., Bammens, L., Benilova, I., Vandersteen, A., Benurwar, M., Borgers, M., et al. The mechanism of γ-Secretase dysfunction in familial Alzheimer disease. EMBO J 31 (2012), 2261–2274.
20. Kretner, B., Trambauer, J., Fukumori, A., Mielke, J., Kuhn, P.-H., Kremmer, E., et al. Generation and deposition of Aβ43 by the virtually inactive presenilin-1 L435F mutant contradicts the presenilin loss-of-function hypothesis of Alzheimer's disease. EMBO Mol Med 8 (2016), 458–465.
21. Woodruff, G., Young, J.E., Martinez, F.J., Buen, F., Gore, A., Kinaga, J., et al. The presenilin-1 dE9 mutation results in reduced gamma-secretase activity, but not total loss of PS1 function, in isogenic human stem cells. Cell Rep 5 (2013), 974–985.
22. Sun, L., Zhou, R., Yang, G., Shi, Y., Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of Aβ42 and Aβ40 peptides by γ-secretase. Proc Natl Acad Sci U S A 114 (2017), E476–E485.
23. Nicolaou, M., Song, Y.Q., Sato, C.A., Orlacchio, A., Kawarai, T., Medeiros, H., et al. Mutations in the open reading frame of the beta-site APP cleaving enzyme (BACE) locus are not a common cause of Alzheimer's disease. Neurogenetics 3 (2001), 203–206.
24. Kim, M., Suh, J., Romano, D., Truong, M.H., Mullin, K., Hooli, B., et al. Potential late-onset Alzheimer's disease-associated mutations in the ADAM10 gene attenuate alpha-secretase activity. Hum Mol Genet 18 (2009), 3987–3996.
25. Suh, J., Choi, S., Romano, D.M., Gannon, M.A., Lesinski, A.N., Kim, D.Y., Tanzi, R.E., ADAM10 missense mutations potentiate beta-Amyloid accumulation by impairing prodomain chaperone function. Neuron 80 (2013), 385–401.
26. Gibson, G., Rare and common variants: Twenty arguments. Nat Rev Genet 13 (2011), 135–145.
27. Naj, A.C., Jun, G., Beecham, G.W., Wang, L.S., Vardarajan, B.N., Buros, J., et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet 43 (2011), 436–441.
28. Lambert, J., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 41 (2009), 1088–1093.
29. Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M.L., et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 41 (2009), 1088–1093.
30. Hollingworth, P., Harold, D., Sims, R., Gerrish, A., Lambert, J.C., Carrasquillo, M.M., et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet 43 (2011), 429–435.
31. Jun, G., Naj, A.C., Beecham, G.W., Wang, L.-S., Buros, J., Gallins, P.J., et al. Meta-analysis confirms CR1, CLU, and PICALM as Alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch Neurol 67 (2010), 1473–1484.
32. Lambert, J.C., Ibrahim-Verbaas, C.A., Harold, D., Naj, A.C., Sims, R., Bellenguez, C., et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet 45 (2013), 1452–1458.
33. Karch, C.M., Cruchaga, C., Goate, A.M., Alzheimer's disease genetics: From the bench to the clinic. Neuron 83 (2014), 11–26.
34. Reitz, C., Wang, L., Lin, C., Larson, E.B., Graff-radford, N.R., Evans, D., et al. Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E4, and the risk of late-onset Alzheimer disease in African Americans. J Am Med Assoc 309 (2013), 1483–1492.
35. Miyashita, A., Koike, A., Jun, G., Wang, L.S., Takahashi, S., Matsubara, E., et al. SORL1 is genetically associated with late-onset Alzheimer's disease in Japanese, Koreans and Caucasians. PLoS One, 8, 2013, e58618.
36. Bateman, R.J., Xiong, C., Benzinger, T.L.S., Fagan, A.M., Goate, A., Fox, N.C., et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 367 (2012), 795–804.
37. Spampinato, M., Rumboldt, Z., Hosker, R., Mintzer, J., Alzheimer's Disease Neuroimaging Initiative. Apolipoprotein E and gray matter volume loss in patients with mild cognitive impairment and Alzheimer disease. Radiology 258 (2011), 843–852.
38. Cruchaga, C., Kauwe, J.S.K., Harari, O., Jin, S.C., Cai, Y., Karch, C.M., et al. GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease. Neuron 78 (2013), 256–268.
39. Schott, J.M., Crutch, S.J., Carrasquillo, M.M., Uphill, J., Shakespeare, T.J., Ryan, N.S., et al. Genetic risk factors for posterior cortical atrophy. Alzheimer's Dement 11 (2015), P168–P169.
40. Stranger, B.E., Stahl, E.A., Raj, T., Progress and promise of genome-wide association studies for human complex trait genetics. Genetics 187 (2011), 367–383.
41. Lonsdale, J., Thomas, J., Salvatore, M., Phillips, R., Lo, E., Shad, S., et al. The Genotype-Tissue Expression (GTEx) project. Nat Genet 45 (2013), 580–585.
42. Ramasamy, A., Trabzuni, D., Guelfi, S., Varghese, V., Smith, C., Walker, R., et al. Genetic variability in the regulation of gene expression in ten regions of the human brain. Nat Neurosci 17 (2014), 1418–1428.
43. Bernstein, B.E., Stamatoyannopoulos, J.A., Costello, J.F., Ren, B., Milosavljevic, A., Meissner, A., et al. The NIH Roadmap Epigenomics Mapping Consortium. Nat Biotechnol 28 (2010), 1045–1048.
44. Bennett, D.A., Wilson, R.S., Arvanitakis, Z., Boyle, P.A., De Toledo-Morrell, L., Schneider, J.A., Selected findings from the religious orders study and rush memory and aging project. J Alzheimer's Dis 33:suppl 1 (2013), S397–S403.
45. Raj, T., Rothamel, K., Mostafavi, S., Ye, C., Lee, M.N., Replogle, J.M., et al. Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes. Science 344 (2014), 519–523.
46. Li, Y.I., Geijn B Van De, Raj, A., Knowles, D.A., Petti, A.A., Golan, D., et al. RNA splicing is a primary link between genetic variation and disease. Science 352 (2016), 600–604.
47. Bonder, M.J., Luijk, R., Zhernakova, D.V., Moed, M., Deelen, P., Vermaat, M., et al. Disease variants alter transcription factor levels and methylation of their binding sites. Nat Genet 49 (2017), 131–138.
48. De Jager, P.L., Srivastava, G., Lunnon, K., Burgess, J., Schalkwyk, L.C., Yu, L., et al. Alzheimer's disease: Early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci. Nat Neurosci 17 (2014), 1156–1163.
49. Lunnon, K., Smith, R., Hannon, E., De Jager, P.L., Srivastava, G., Volta, M., et al. Methylomic profiling implicates cortical deregulation of ANK1 in Alzheimer's disease. Nat Neurosci 17 (2014), 1164–1170.
50. Gjoneska, E., Pfenning, A.R., Mathys, H., Quon, G., Kundaje, A., Tsai, L.-H., Kellis, M., Conserved epigenomic signals in mice and humans reveal immune basis of Alzheimer's disease. Nature 518 (2015), 365–369.
51. Chick, J.M., Munger, S.C., Simecek, P., Huttlin, E.L., Choi, K., Daniel, M., Defining the consequences of genetic variation on a proteome-wide scale. Nature 534 (2016), 500–505.
52. Akbarian, S., Liu, C., Knowles, J.A., Vaccarino, F.M., Farnham, P.J., Crawford, G.E., et al. The PsychENCODE project. Nat Neurosci 18 (2015), 1707–1712.
53. Kaikkonen, M.U., Spann, N.J., Heinz, S., Romanoski, C.E., Allison, K.A., Stender, J.D., et al. Remodeling of the enhancer landscape during macrophage activation is coupled to enhancer transcription. Mol Cell 51 (2013), 310–325.
54. Chen, L., Ge, B., Casale, F.P., Vasquez, L., Kwan, T., Garrido-Martin, D., et al. Genetic drivers of epigenetic and transcriptional variation in human immune cells. Cell 167 (2016), 1398–1414.
55. Gaiteri, C., Mostafavi, S., Honey, C.J., De Jager, P.L., Bennett, D.A., Genetic variants in Alzheimer disease - molecular and brain network approaches. Nat Rev Neurol 12 (2016), 413–427.
56. Fromer, M., Roussos, P., Sieberts, S.K., Johnson, J.S., Kavanagh, D.H., Perumal, T.M., et al. Gene expression elucidates functional impact of polygenic risk for schizophrenia. Nat Neurosci 19 (2016), 1442–1453.
57. Zhang, B., Gaiteri, C., Bodea, L.-G., Wang, Z., McElwee, J., Podtelezhnikov, A.A., et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. Cell 153 (2013), 707–720.
58. Pottier, C., Ravenscroft, T.A., Brown, P.H., Finch, N.A., Baker, M., Parsons, M., et al. TYROBP genetic variants in early-onset Alzheimer's disease. Neurobiol Aging, 48, 2016 222.e9–15.
59. Seyfried, N.T., Dammer, E.B., Swarup, V., Nandakumar, D., Duong, D.M., Yin, L., et al. A multi-network approach identifies protein-specific co-expression in asymptomatic and symptomatic Alzheimer's Disease. Cell Syst 4 (2016), 60–72.e4.
60. Jonsson, T., Atwal, J.K., Steinberg, S., Snaedal, J., Jonsson, P.V., Bjornsson, S., et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488 (2012), 96–99.
61. Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P.V., Snaedal, J., et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med 368 (2012), 107–116.
62. Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., et al. TREM2 variants in Alzheimer's disease. N Engl J Med 368 (2013), 117–127.
63. Steinberg, S., Stefansson, H., Jonsson, T., Johannsdottir, H., Ingason, A., Helgason, H., et al. Loss-of-function variants in ABCA7 confer risk of Alzheimer's disease. Nat Genet 47 (2015), 445–447.
64. Jin, S.C., Benitez, B.A., Karch, C.M., Cooper, B., Skorupa, T., Carrell, D., et al. Coding variants in TREM2 increase risk for Alzheimer's disease. Hum Mol Genet 23 (2014), 5838–5846.
65. Pottier, C., Wallon, D., Rousseau, S., Rovelet-Lecrux, A., Richard, A.C., Rollin-Sillaire, A., et al. TREM2 R47H variant as a risk factor for early-onset Alzheimer's disease. J Alzheimer's Dis 35 (2013), 45–49.
66. Vardarajan, B.N., Ghani, M., Kahn, A., Sheikh, S., Sato, C., Barral, S., et al. Rare coding mutations identified by sequencing of Alzheimer disease genome-wide association studies loci. Ann Neurol 78 (2015), 487–498.
67. Cuyvers, E., De Roeck, A., Van den Bossche, T., Van Cauwenberghe, C., Bettens, K., Vermeulen, S., et al. Mutations in ABCA7 in a Belgian cohort of Alzheimer's disease patients: A targeted resequencing study. Lancet Neurol 14 (2015), 814–822.
68. Cruchaga, C., Karch, C.M., Jin, S.C., Benitez, B.A., Cai, Y., Guerreiro, R., et al. Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease. Nature 505 (2015), 550–554.
69. Wetzel-Smith, M.K., Hunkapiller, J., Bhangale, T.R., Srinivasan, K., Maloney, J.A., Atwal, J.K., et al. A rare mutation in UNC5C predisposes to late-onset Alzheimer's disease and increases neuronal cell death. Nat Med 20 (2014), 1452–1457.
70. Logue, M.W., Schu, M., Vardarajan, B.N., Farrell, J., Bennett, D.A., Buxbaum, J.D., et al. Two rare AKAP9 variants are associated with Alzheimer's disease in African Americans. Alzheimers Dement 10 (2014), 609–618.
71. Jones, L., Lambert, J.C., Wang, L.S., Choi, S.H., Harold, D., Vedernikov, A., et al. Convergent genetic and expression data implicate immunity in Alzheimer's disease. Alzheimer's Dement 11 (2015), 658–671.
72. Corder, E.H., Saunders, A.M., Strittmatter, W.J., Schmechel, D.E., Gaskell, P.C., Small, G.W., et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261 (1993), 921–923.
73. Strittmatter, W.J., Saunders, A.M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G.S., Roses, A.D., Apolipoprotein E: High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 90 (1993), 1977–1981.
74. Kim, J., Basak, J.M., Holtzman, D.M., The role of apolipoprotein E in Alzheimer's disease. Neuron 63 (2009), 287–303.
75. Fryer, J.D., Simmons, K., Parsadanian, M., Bales, K., Paul, S.M., Sullivan, P.M., Holtzman, D.M., Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. J Neurosci 25 (2005), 2803–2810.
76. Castellano, J.M., Kim, J., Stewart, F.R., Jiang, H., DeMattos, R.B., Patterson, B.W., et al. Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci Transl Med, 3, 2011, 89ra57.
77. Riddell, D.R., Zhou, H., Atchison, K., Warwick, H.K., Atkinson, P.J., Jefferson, J., et al. Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels. J Neurosci 28 (2008), 11445–11453.
78. Chung, W.-S., Verghese, P.B., Chakraborty, C., Joung, J., Hyman, B.T., Ulrich, J.D., et al. Novel allele-dependent role for APOE in controlling the rate of synapse pruning by astrocytes. Proc Natl Acad Sci U S A 113 (2016), 10186–10191.
79. Guerreiro, R.J., Beck, J., Gibbs, J.R., Santana, I., Rossor, M.N., Schott, J.M., et al. Genetic variability in CLU and its association with Alzheimer's disease. PLoS One, 5, 2010, e9510.
80. DeMattos, R.B., Cirrito, J.R., Parsadanian, M., May, P.C., O'Dell, M.A., Taylor, J.W., et al. ApoE and clusterin cooperatively suppress Abeta levels and deposition: Evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron 41 (2004), 193–202.
81. Braskie, M.N., Jahanshad, N., Stein, J.L., Barysheva, M., McMahon, K.L., de Zubicaray, G.I., et al. Common Alzheimer's disease risk variant within the CLU gene affects white matter microstructure in young adults. J Neurosci 31 (2011), 6764–6770.
82. Erk, S., Meyer-Lindenberg, A., Opitz von Boberfeld, C., Esslinger, C., Schnell, K., Kirsch, P., et al. Hippocampal function in healthy carriers of the CLU Alzheimer's disease risk variant. J Neurosci 31 (2011), 18180–18184.
83. Bettens, K., Brouwers, N., Engelborghs, S., Lambert, J.-C., Rogaeva, E., Vandenberghe, R., et al. Both common variations and rare non-synonymous substitutions and small insertion/deletions in CLU are associated with increased Alzheimer risk. Mol Neurodegener, 7, 2012, 3.
84. Bettens, K., Vermeulen, S., Van Cauwenberghe, C., Heeman, B., Asselbergh, B., Robberecht, C., et al. Reduced secreted clusterin as a mechanism for Alzheimer-associated CLU mutations. Mol Neurodegener, 10, 2015, 30.
85. Cukier, H.N., Kunkle, B.W., Vardarajan, B.N., Rolati, S., Hamilton-Nelson, K.L., Kohli, M.A., et al. ABCA7 frameshift deletion associated with Alzheimer's disease in African Americans. Neurol Genet, 2, 2016, e79.
86. Le Guennec, K., Quenez, O., Charbonnier, C., Wallon, D., Grenier-Boley, B., Richard, A., et al. ABCA7 rare variants and Alzheimer disease risk. Neurology 86 (2016), 2134–2137.
87. Jehle, A.W., Gardai, S.J., Li, S., Linsel-Nitschke, P., Morimoto, K., Janssen, W.J., et al. ATP-binding cassette transporter A7 enhances phagocytosis of apoptotic cells and associated ERK signaling in macrophages. J Cell Biol 174 (2006), 547–556.
88. Chan, S.L., Kim, W.S., Kwok, J.B., Hill, A.F., Cappai, R., Rye, K.A., Garner, B., ATP-binding cassette transporter A7 regulates processing of amyloid precursor protein in vitro. J Neurochem 106 (2008), 793–804.
89. Kim, W.S., Li, H., Ruberu, K., Chan, S., Elliott, D.A., Low, J.K., et al. Deletion of Abca7 increases cerebral amyloid-β accumulation in the J20 mouse model of Alzheimer's disease. J Neurosci 33 (2013), 4387–4394.
90. Sakae, N., Liu, C.-C., Shinohara, M., Frisch-Daiello, J., Ma, L., Yamazaki, Y., et al. ABCA7 deficiency accelerates Amyloid-beta generation and Alzheimer's neuronal pathology. J Neurosci 36 (2016), 3848–3859.
91. Ramirez, L.M., Goukasian, N., Porat, S., Hwang, K.S., Eastman, J.A., Hurtz, S., et al. Common variants in ABCA7 and MS4A6A are associated with cortical and hippocampal atrophy. Neurobiol Aging 39 (2016), 82–89.
92. Rogaeva, E., Meng, Y., Lee, J.H., Gu, Y., Kawarai, T., Zou, F., et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet 39 (2007), 168–177.
93. Pottier, C., Hannequin, D., Coutant, S., Rovelet-Lecrux, A., Wallon, D., Rousseau, S., et al. High frequency of potentially pathogenic SORL1 mutations in autosomal dominant early-onset Alzheimer disease. Mol Psychiatry 17 (2012), 875–879.
94. Andersen, O.M., Reiche, J., Schmidt, V., Gotthardt, M., Spoelgen, R., Behlke, J., et al. Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc Natl Acad Sci U S A 102 (2005), 13461–13466.
95. Caglayan, S., Takagi-Niidome, S., Liao, F., Carlo, A.-S., Schmidt, V., Burgert, T., et al. Lysosomal sorting of amyloid-β by the SORLA receptor is impaired by a familial Alzheimer's disease mutation. Sci Transl Med, 6, 2014, 223ra20.
96. Dodson, S.E., Andersen, O.M., Karmali, V., Fritz, J.J., Cheng, D., Peng, J., et al. Loss of LR11/SORLA enhances early pathology in a mouse model of amyloidosis: Evidence for a proximal role in Alzheimer's disease. J Neurosci 28 (2008), 12877–12886.
97. Chapuis, J., Hansmannel, F., Gistelinck, M., Mounier, A., Van Cauwenberghe, C., Kolen, K.V., et al. Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology. Mol Psychiatry 18 (2013), 1225–1234.
98. Lambert, J.C., Zelenika, D., Hiltunen, M., Chouraki, V., Combarros, O., Bullido, M.J., et al. Evidence of the association of BIN1 and PICALM with the AD risk in contrasting European populations. Neurobiol Aging, 32, 2011 756.e11–e15.
99. Wijsman, E.M., Pankratz, N.D., Choi, Y., Rothstein, J.H., Faber, K.M., Cheng, R., et al. Genome-wide association of familial late-onset Alzheimer's disease replicates BIN1 and CLU and nominates CUGBP2 in interaction with APOE. PLoS Genet, 7, 2011, e1001308.
100. Calafate, S., Flavin, W., Verstreken, P., Moechars, D., Loss of Bin1 promotes the propagation of tau pathology. Cell Rep 17 (2016), 931–940.
101. Miyagawa, T., Ebinuma, I., Morohashi, Y., Hori, Y., Young Chang, M., Hattori, H., et al. BIN1 regulates BACE1 intracellular trafficking and amyloid-β production. Hum Mol Genet Genet 25 (2016), 2948–2958.
102. De Rossi, P., Buggia-Prévot, V., Clayton, B.L.L., Vasquez, J.B., van Sanford, C., Andrew, R.J., et al. Predominant expression of Alzheimer's disease-associated BIN1 in mature oligodendrocytes and localization to white matter tracts. Mol Neurodegener, 11, 2016, 59.
103. Ubelmann, F., Burrinha, T., Salavessa, L., Gomes, R., Ferreira, C., Moreno, N., Guimas Almeida, C., Bin1 and CD2AP polarise the endocytic generation of beta-amyloid. EMBO Rep 18 (2017), 102–122.
104. Liao, F., Zhang, T.J., Mahan, T.E., Jiang, H., Holtzman, D.M., Effects of CD2-associated protein deficiency on amyloid-β in neuroblastoma cells and in an APP transgenic mouse model. Brain Behav Immun 47 (2015), 163–171.
105. Cochran, J.N., Rush, T., Buckingham, S.C., Roberson, E.D., The Alzheimer's disease risk factor CD2AP maintains blood-brain barrier integrity. Hum Mol Genet 24 (2015), 6667–6674.
106. Tian, Y., Chang, J.C., Fan, E.Y., Flajolet, M., Greengard, P., Adaptor complex AP2/PICALM, through interaction with LC3, targets Alzheimer's APP-CTF for terminal degradation via autophagy. Proc Natl Acad Sci U S A 110 (2013), 17071–17076.
107. Kanatsu, K., Morohashi, Y., Suzuki, M., Kuroda, H., Watanabe, T., Tomita, T., Iwatsubo, T., Decreased CALM expression reduces Aβ42 to total Aβ ratio through clathrin-mediated endocytosis of γ-secretase. Nat Commun, 5, 2014, 3386.
108. Kanatsu, K., Hori, Y., Takatori, S., Watanabe, T., Iwatsubo, T., Tomita, T., Partial loss of CALM function reduces Aβ42 production and amyloid deposition in vivo. Hum Mol Genet 25 (2016), 3988–3997.
109. Xiao, Q., Gil, S.C., Yan, P., Wang, Y., Han, S., Gonzales, E., et al. Role of phosphatidylinositol clathrin assembly lymphoid-myeloid leukemia (PICALM) in intracellular amyloid precursor protein (APP) processing and amyloid plaque pathogenesis. J Biol Chem 287 (2012), 21279–21289.
110. Zhao, Z., Sagare, A.P., Ma, Q., Halliday, M.R., Kong, P., Kisler, K., et al. Central role for PICALM in amyloid-β blood-brain barrier transcytosis and clearance. Nat Neurosci 18 (2015), 978–987.
111. Barbosa, A.C., Kim, M.-S., Ertunc, M., Adachi, M., Nelson, E.D., McAnally, J., et al. MEF2C, a transcription factor that facilitates learning and memory by negative regulation of synapse numbers and function. Proc Natl Acad Sci U S A 105 (2008), 9391–9396.
112. Hsin, H., Kim, M., Wang, C., Sheng, M., Proline-rich tyrosine kinase 2 regulates hippocampal long-term depression. J Neurosci 30 (2010), 11983–11993.
113. Zhang, Y., Sloan, S.A., Clarke, L.E., Caneda, C., Plaza, C.A., Blumenthal, P.D., et al. Purification and characterization of progenitor and mature human astrocytes reveals transcriptional and functional differences with mouse. Neuron 89 (2016), 37–53.
114. Crehan, H., Hardy, J., Pocock, J., Blockage of CR1 prevents activation of rodent microglia. Neurobiol Dis 54 (2013), 139–149.
115. Yasojima, K., Schwab, C., McGeer, E.G., McGeer, P.L., Up-regulated production and activation of the complement system in Alzheimer's disease brain. Am J Pathol 154 (1999), 927–936.
116. Hong, S., Beja-Glasser, V.F., Nfonoyim, B.M., Frouin, A., Li, S., Ramakrishnan, S., et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 352 (2016), 712–716.
117. Brouwers, N., Van Cauwenberghe, C., Engelborghs, S., Lambert, J.-C., Bettens, K., Le Bastard, N., et al. Alzheimer risk associated with a copy number variation in the complement receptor 1 increasing C3b/C4b binding sites. Mol Psychiatry 17 (2012), 223–233.
118. Raj, T., Ryan, K.J., Replogle, J.M., Chibnik, L.B., Rosenkrantz, L., Tang, A., et al. CD33: increased inclusion of exon 2 implicates the Ig V-set domain in Alzheimer's disease susceptibility. Hum Mol Genet 23 (2014), 2729–2736.
119. Malik, M., Simpson, J.F., Parikh, I., Wilfred, B.R., Fardo, D.W., Nelson, P.T., Estus, S., CD33 Alzheimer's risk-altering polymorphism, CD33 expression, and exon 2 splicing. J Neurosci 33 (2013), 13320–13325.
120. Griciuc, A., Serrano-Pozo, A., Parrado, A.R., Lesinski, A.N., Asselin, C.N., Mullin, K., et al. Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron 78 (2013), 631–643.
121. Bradshaw, E.M., Chibnik, L.B., Keenan, B.T., Ottoboni, L., Raj, T., Tang, A., et al. CD33 Alzheimer's disease locus: Altered monocyte function and amyloid biology. Nat Neurosci 16 (2013), 848–850.
122. Chan, G., White, C.C., Winn, P.A., Cimpean, M., Replogle, J.M., Glick, L.R., et al. CD33 modulates TREM2: Convergence of Alzheimer loci. Nat Neurosci 18 (2015), 1556–1558.
123. Paloneva, J., Manninen, T., Christman, G., Hovanes, K., Mandelin, J., Adolfsson, R., et al. Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. Am J Hum Genet 71 (2002), 656–662.
124. Suárez-Calvet, M., Kleinberger, G., Araque Caballero, M.Á., Brendel, M., Rominger, A., Alcolea, D., et al. sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers. EMBO Mol Med, 8, 2016, e201506123.
125. Piccio, L., Deming, Y., Del-Águila, J.L., Ghezzi, L., Holtzman, D.M., Fagan, A.M., et al. Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathol 131 (2016), 925–933.
126. Colonna, M., Wang, Y., TREM2 variants: New keys to decipher Alzheimer disease pathogenesis. Nat Rev Neurosci 17 (2016), 201–207.
127. Kleinberger, G., Yamanishi, Y., Suárez-Calvet, M., Czirr, E., Lohmann, E., Cuyvers, E., et al. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med, 6, 2014, 243ra86.
128. Wang, Y., Cella, M., Mallinson, K., Ulrich, J.D., Young, K.L., Robinette, M.L., et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell 160 (2015), 1061–1071.
129. Atagi, Y., Liu, C.-C., Painter, M.M., Chen, X.-F., Verbeeck, C., Zheng, H., et al. Apolipoprotein E is a ligand for triggering receptor expressed on myeloid cells 2 (TREM2). J Biol Chem 290 (2015), 26043–26050.
130. Bailey, C.C., Devaux, L.B., Farzan, M., The triggering receptor expressed on myeloid cells 2 binds apolipoprotein E. J Biol Chem 290 (2015), 26033–26042.
131. Yeh, F.L., Wang, Y., Tom, I., Gonzalez, L.C., Sheng, M., TREM2 binds to apolipoproteins, including APOE and CLU/APOJ, and thereby facilitates uptake of amyloid-beta by microglia. Neuron 91 (2016), 328–340.
132. Jay, T.R., Hirsch, A.M., Broihier, M.L., Miller, C.M., Neilson, L.E., Ransohoff, R.M., et al. Disease progression-dependent effects of TREM2 deficiency in a mouse model of Alzheimer's disease. J Neurosci 37 (2016), 637–647.
133. Eon Kuek, L., Leffler, M., Mackay, G.A., Hulett, M.D., The MS4A family: Counting past 1, 2 and 3. Immunol Cell Biol 94 (2016), 11–23.
134. Wang, J., Shiratori, I., Uehori, J., Ikawa, M., Arase, H., Neutrophil infiltration during inflammation is regulated by PILRα via modulation of integrin activation. Nat Immunol 14 (2013), 34–40.
135. Karch, C.M., Jeng, A.T., Nowotny, P., Cady, J., Cruchaga, C., Goate, A.M., Expression of novel Alzheimer's disease risk genes in control and Alzheimer's disease brains. PLoS One, 7, 2012, e50976.
136. Huang, K.L., Marcora, E., Pimenova, A.A., Di Narzo, A.F., Kapoor, M., Jin, S.C., et al. A common haplotype lowers PU.1 expression in myeloid cells and delays onset of Alzheimer's disease. Nat Neurosci 20 (2017), 1052–1061.
137. Sims, R., van der Lee, S.J., Naj, A.C., Bellenguez, C., Badarinarayan, N., Jakobsdottir, J., et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nat Genet 49 (2017), 1373–1384.
138. Liu, J.Z., Erlich, Y., Pickrell, J.K., Case–control association mapping by proxy using family history of disease. Nat Genet 49 (2017), 325–331.
139. Jun, G.R., Chung, J., Mez, J., Barber, R., Beecham, G.W., Bennett, D.A., et al. Transethnic genome-wide scan identifies novel Alzheimer's disease loci. Alzheimer's Dement 13 (2017), 727–738.
140. Ran, F.A., Hsu, P.D., Wright, J., Agarwala, V., Scott, D.A., Zhang, F., Genome engineering using the CRISPR-Cas9 system. Nat Protoc 8 (2013), 2281–2308.
141. Karch, C.M., Ezerskiy, L.A., Bertelsen, S.ADGC, Goate, A.M., Alzheimer's disease risk polymorphisms regulate gene expression in the ZCWPW1 and the CELF1 loci. PLoS One, 11, 2016, e0148717.
142. Nicolas, G., Charbonnier, C., Wallon, D., Quenez, O., Bellenguez, C., Grenier-Boley, B., et al. SORL1 rare variants: A major risk factor for familial early-onset Alzheimer's disease. Mol Psychiatry 21 (2015), 831–836.
143. Ruiz, A., Heilmann, S., Becker, T., Hernández, I., Wagner, H., Thelen, M., et al. Follow-up of loci from the International Genomics of Alzheimer's Disease Project identifies TRIP4 as a novel susceptibility gene. Transl Psychiatry, 4, 2014, e358.
144. Benitez, B.A., Jin, S.C., Guerreiro, R., Graham, R., Lord, J., Harold, D., et al. Missense variant in TREML2 protects against Alzheimer's disease. Neurobiol Aging, 35, 2014 1510.e19–e26.